EE12 A Probabilistic Cost-Effectiveness Analysis of Venetoclax and Obinutuzumab As a First-Line, 12-Month, Fixed Duration Therapy in Chronic Lymphocytic Leukemia (CLL) in Canada
Abstract
Authors
A Chatterjee G van de Wetering R Goeree C Owen S Barakat BS Manzoor K Sail